STX-721, a covalent EGFR/HER2 exon 20 inhibitor, takes advantage of exon 20 mutant dynamic protein states and achieves unique mutant-selectivity across human cancer models
Pagliarini, R.A., Henderson, J.A., Borrelli, D.R., Brooijmans, N., Hilbert, B.J., Huff, M.R., Ito, T., Kryukov, G., Ladd, B., Martin, B., Milgram, B.C., Motiwala, H., OHearn, E., Wang, W., Hata, A., Bellier, J., Kuzmic, P., Guzman-Perez, A., Jackson, E.L., Stuart, D.To be published.